Emergent BioSolutions

EMERGENT BIOSOLUTIONS INC

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.

Screenshot 2025-03-19 at 8.55.22 PM

Biotech

BVNKF

TNXP

As Mpox Cases Spread Around The World, Tonix Pharmaceuticals&#39; Single-Dose Vaccine TNX-801 Has Potential To Slow The Spread

WallStreet.NYSE

Large Cap

Market Summary

News

Sector ETFs

Broad U.S. Equity ETFs

Global

Movers

ETFs

General

$BTC

ASTS

AVAV

CHPT

CRWD

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

DAVE

SPDR Dow Jones Industrial Average ETF Trust

GTLB

OKTA

RIGL

RILY

ROST

STEM

iShares Trust Barclays 20+ Year Treasury Bond Fund

Select Sector SPDR-Consumer Discretionary

U.S. stocks plunged Tuesday as President Donald Trump‘s tariffs on key trade partners came into effect, prompting retaliatory measures and intensifying global trade tensions.

Stocks Drop As Trade War Escalates: What&#39;s Driving Markets Tuesday?

Wall Street Cautiously Optimistic About 2025, S&P 500 Projected To Rise 9-10%: CNBC Strategist Survey

Equities

Bonds

Markets

Tech

$ETH

AMZN

AVGO

BHVN

FTRE

IBRX

NABL

NOVA

SAVA

TSLA

Stocks fell broadly on Monday to start the month of March with all three major indices red in midday trading. Investors digested a decline in February&#39;s ISM Manufacturing PMI data which fell to 50.3%, down from 50.9% in January. 

Tesla Rebounds While Tariffs Weigh On Manufacturing: What&#39;s Driving Markets Monday?

Emergent BioSolutions Inc

EMPIRE BANCSHARES INC by Empire Bancshares Inc.

Empire Bancshares Inc

Health Care

Press Releases

Emergent BioSolutions and Pro Football Legend Emmitt Smith Raise Awareness of Ready to Rescue Campaign Timed to the Big Game in New Orleans

Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

Earnings

Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results

Financing

Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International

Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates

Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs

Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products

Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International

Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg

Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08

HKMPY

Abeona Therapeutics

Annexon

aTyr Pharma

Aura Biosciences

Benitec Biopharma

Cidara Therapeutics

COMPASS Pathways Plc - American Depository Shares

Compass Pathways

Compass Therapeutics, Inc. - Common Stock

Compass Therapeutics

Design Therapeutics

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics

Gossamer Bio

Humacyte

Immutep Limited - American Depositary Shares

Immutep

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals

ITeos Therapeutics

Monopar Therapeutics

Anbio Biotechnology - Class A Ordinary Shares

Anbio Biotechnology

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals

Prime Medicine

Palvella Therapeutics, Inc. - Common Stock

Palvella Therapeutics

AVITA Medical

Rigel Pharmaceuticals, Inc. - Common Stock

Rigel Pharmaceuticals

2seventy bio

Vanda Pharmaceuticals Inc. - Common Stock

Vanda Pharmaceuticals

XOMA Royalty

HC Wainwright & Co.

Benchmark

Rodman & Renshaw

Chardan Capital

Screenshot 2024-09-18 at 12.30.33 AM

New Hope For Mpox? How TNX-801 Could Meet The WHO&#39;s Vaccine Targets For A Safer, Single-Dose Solution

Comments

Emergent BioSolutions

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga